Live-Attenuated Influenza Viruses of Vaccine
- Therapeutic Biological Agents
Key Problem and Market Opportunity
- Live attenuated influenza vaccine (LAIV) is generally regarded to be superior to traditional inactivated vaccines for the noninvasive mean of administration and stimulation of stronger immune responses. Currently, the only FDA approved LAIV is FluMist. However, recent studies showed that FluMist is not very effective. In addition, the production cost is high since the vaccine needs to be produced in human cell lines.
- The global influenza vaccines market is estimated to reach US$ 5 billion by 2021 according to Research and Markets. Increasing awareness about the pandemic influenza viruses and increasing government involvement for vaccination against influenza viruses are the major driving forces for the market growth during the forecast period.
Key Advantages of the Technology
- This technology provides a novel approach to make a human mutant influenza virus by converting its codon usage so that it is similar to that observed from avian influenza viruses.
- Two mutant viruses generated by this approach are significantly attenuated in mammalian cells and mice, yet grow well in embryonated eggs. Therefore they are safe to be used in human and they can be produced in low cost egg-based vaccine manufacturing system.
- A single dose of intranasal vaccination of the attenuated viruses in mouse models induces potent innate, humoral, and cellular immune responses, and it could protect mice against homologous and heterologous viral challenges.
- The attenuated viruses could also be used as vaccine master donor strains for making different influenza vaccines by introducing hemagglutinin and neuraminidase genes derived from other strains.
Potential Product and Services
- Two attenuated influenza viral master strains that have strong protective effects and can be used to make different seasonal influenza vaccines
- Customized seasonal influenza vaccines derived from the master strains
Development Status and IP Strength
- Influenza viral master strains are available.
- Some influenza vaccine prototypes are produced based on the master strains.
- PCT application No. PCT/CN2016/084715 and US application No. 15/174,348 were filed in June 2016.